Logo image of HOTH

HOTH THERAPEUTICS INC (HOTH) Stock Fundamental Analysis

NASDAQ:HOTH - Nasdaq - US44148G2049 - Common Stock - Currency: USD

1.21  +0.01 (+0.83%)

After market: 1.22 +0.01 (+0.83%)

Fundamental Rating

3

Overall HOTH gets a fundamental rating of 3 out of 10. We evaluated HOTH against 195 industry peers in the Pharmaceuticals industry. HOTH has a great financial health rating, but its profitability evaluates not so good. HOTH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HOTH has reported negative net income.
HOTH had a negative operating cash flow in the past year.
HOTH had negative earnings in each of the past 5 years.
In the past 5 years HOTH always reported negative operating cash flow.
HOTH Yearly Net Income VS EBIT VS OCF VS FCFHOTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

HOTH has a worse Return On Assets (-77.89%) than 71.79% of its industry peers.
HOTH has a Return On Equity (-83.39%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -77.89%
ROE -83.39%
ROIC N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
HOTH Yearly ROA, ROE, ROICHOTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HOTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOTH Yearly Profit, Operating, Gross MarginsHOTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

HOTH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HOTH has been increased compared to 5 years ago.
There is no outstanding debt for HOTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HOTH Yearly Shares OutstandingHOTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
HOTH Yearly Total Debt VS Total AssetsHOTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 3.06 indicates that HOTH is not in any danger for bankruptcy at the moment.
HOTH has a Altman-Z score of 3.06. This is in the better half of the industry: HOTH outperforms 75.90% of its industry peers.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.06
ROIC/WACCN/A
WACCN/A
HOTH Yearly LT Debt VS Equity VS FCFHOTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

HOTH has a Current Ratio of 15.08. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
HOTH has a better Current ratio (15.08) than 87.18% of its industry peers.
HOTH has a Quick Ratio of 15.08. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HOTH (15.08) is better than 87.18% of its industry peers.
Industry RankSector Rank
Current Ratio 15.08
Quick Ratio 15.08
HOTH Yearly Current Assets VS Current LiabilitesHOTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.54% over the past year.
EPS 1Y (TTM)41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HOTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.53% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.86%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOTH Yearly Revenue VS EstimatesHOTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
HOTH Yearly EPS VS EstimatesHOTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HOTH. In the last year negative earnings were reported.
Also next year HOTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOTH Price Earnings VS Forward Price EarningsHOTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOTH Per share dataHOTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as HOTH's earnings are expected to grow with 13.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.4%
EPS Next 3Y13.53%

More info and screens

0

5. Dividend

5.1 Amount

HOTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOTH THERAPEUTICS INC

NASDAQ:HOTH (7/3/2025, 7:34:12 PM)

After market: 1.22 +0.01 (+0.83%)

1.21

+0.01 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners2.31%
Inst Owner Change25.03%
Ins Owners0.49%
Ins Owner Change0%
Market Cap15.98M
Analysts82.5
Price Target4.59 (279.34%)
Short Float %8.77%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.7%
Min EPS beat(2)-1.81%
Max EPS beat(2)15.21%
EPS beat(4)3
Avg EPS beat(4)17.32%
Min EPS beat(4)-1.81%
Max EPS beat(4)45.28%
EPS beat(8)6
Avg EPS beat(8)21.7%
EPS beat(12)9
Avg EPS beat(12)14.55%
EPS beat(16)11
Avg EPS beat(16)12.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.07%
EPS NY rev (1m)0%
EPS NY rev (3m)1.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 1.39
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.89%
ROE -83.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.08
Quick Ratio 15.08
Altman-Z 3.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
EPS Next Y42.86%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.9%
OCF growth 3YN/A
OCF growth 5YN/A